Out-licensors are always asking this fundamental question: what do in-licensors want? “In-licensors” extend far beyond the top 50 companies. At BIO 2013, there were about 1000 drug R&D companies. Approximately 20% were in-licensors and 80% were out-licensors, according to their BIO One-on-One Partnering profiles. According to Thomson Reuters Recap, there were a little over 700 licensing and joint venture deals in 2013, involving about 500 buy-siders/licensees. For more on buy-side deal trends, see our recorded webinar with Recap.
There are two great ways to figure out what the buyers want: 1) check out their partnering and “areas of interest” pages on their website 2) look at their profile in BIO’s One-on-One Partnering System, which often has great up-to-the-minute supplementary information to #1, especially for specific divisions or countries. Access to BIO’s One-on-One Partnering System requires a login based on BIO meeting attendance.
For convenience, I assembled a list of the partnering and “areas of interest” webpages for the top 50 companies, along with the respective BIO One-on-One Partnering webpages. Yes, there are actually more than 50 companies in this list. Since there are different definitions of the ‘top 50’ companies, I took companies from Thomson Reuters Recap, IMS Consulting Group, Current Partnering and even Wikipedia top 50 lists and threw them all in. Enjoy: